GT Molecular, Rapidly Expanding Molecular Diagnostics Biotech, Launches Two Highly Sensitive Tests for the Dangerous UK Variant of SARS-CoV-2

GT Molecular | January 13, 2021

GT Molecular, a quickly extending sub-atomic diagnostics biotech, has dispatched two profoundly delicate tests for the risky UK Variant of SARS-CoV-2 (B.1.1.7). These tale examines expand upon GT Molecular's clinical foundation and technology for profoundly exact and solid qPCR and advanced PCR recognition of SARS-CoV-2 virus and are offered in two formats.

The fee-for-service testing of wastewater for the presence of SARS-CoV-2 and the variations available for use furnishes networks with a quick, exceptionally savvy technique to comprehend the measure of viral transmission inside a local area. Everybody inside a local area gives an example as a flush to the wastewater treatment office and a solitary wastewater test can cover a large number of individuals for a simple portion of what a clinical test for an individual expenses. Moreover, the presence of the infection in wastewater can go before nearby flare-ups locally by as long as seven days, giving wellbeing authorities time to prepare and increase testing.

By applying this technique for local area wastewater checking to the recently coursing UK variation, GT Molecular is the first to go above and beyond and really "genotype the sewer".


we sat down with Absci Founder and CEO, Sean McClain to discuss $ABSI’s mission, vision, and innovations as a member of the Nasdaq Biotechnology Index.


we sat down with Absci Founder and CEO, Sean McClain to discuss $ABSI’s mission, vision, and innovations as a member of the Nasdaq Biotechnology Index.

Related News


MaxCyte Licences With Catamaran Bio to Advance Its CAR-NK Cell Therapy Programs

MaxCyte | January 04, 2023

MaxCyte, a leading commercial cell-engineering company, announced the signing of a strategic platform license (SPL) with Catamaran Bio, a biotechnology enterprise creating off-the-shelf chimeric antigen receptor (CAR)-NK cell therapeutics to cure a wide range of cancers. While Catamaran acquires non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform per the terms of the agreement, in exchange, MaxCyte will receive platform licensing fees and revenue related to its programs. Catamaran is actively developing highly potent allogeneic, cryopreserved CAR-NK cell therapeutics using synthetic biology and non-viral cell engineering capable of treating challenging cancers, including solid tumors, by integrating new functional features with the inherent cancer-fighting properties of NK cells. In addition, the company created the TAILWIND® platform, an integrated set of technologies, to engineer, expand, and process NK cells into safe and effective off-the-shelf cell therapy products for numerous cancer types. The MaxCyte ExPERT™ instrument portfolio is the next generation of clinically verified electroporation technology for complicated and scalable cell creation. The ExPERT™ platform provides the high-end performance required to enable the next era of biological and cellular treatments by delivering high transfection efficiency, seamless scaling, and expanded functionality. MaxCyte's Catamaran agreement is the company's 19th overall SPL. About MaxCyte MaxCyte is a prominent commercial cell-engineering firm dedicated to advancing breakthrough cell-based research and next-generation cell therapy discovery, development, and commercialization. Over the years, it has been developing and commercializing its unique Flow Electroporation® platform, which allows for the intricate creation of a wide range of cells. In addition, its ExPERT™ platform, based on its Flow Electroporation technology, has been created to assist the rapidly increasing cell therapy market and can be used across the high-growth cell therapy sector, from discovery and development to commercialization of next-generation cell-based therapies.

Read More


Benchling Reinforces Security Commitment with Type 2 SOC 2

Benchling | January 27, 2023

On January 27, 2023, Benchling, the R&D cloud that powers the biotechnology sector, announced that it has passed the System and Organization Controls (SOC) 2 certification. Schellman, an independent Certified Public Accounting (CPA) firm, conducted the Type 2 SOC 2 test according to the AICPA's SOC 2 standards. Type 2 SOC 2 evaluates the design and operational performance of an organization's security processes and controls to meet its security goals and customer commitments during a predetermined evaluation period. Constant monitoring, evaluation, and modification of the requirements and security measures guarantee a secure environment for doing business. The CISO at Benchling, Zach Powers, said, "Biotechs are managing an evolving landscape of security and compliance risks, and they require trusted software partners to help them meet these demands." He added, "At Benchling, we make the security, privacy, and compliance of our customers' sensitive data a company-wide, critical investment, not only through Type 2 SOC 2, but also through our best-in-class security team, our trust-but-verify processes, and our adherence to global compliance standards." (Source – PR Newswire) Benchling's R&D Cloud is the biotech R&D platform of choice, trusted by over 1,000 organizations worldwide in highly regulated areas such as biopharmaceuticals, agribusiness, industrials, and consumer packaged goods. Benchling is used by customers to securely store, standardize, and analyze crucial data related to the design and development of innovative biotech products. Benchling's objective is to protect client data; hence, the firm utilizes sophisticated data security and privacy protections and complies with tight regulatory regulations such as the NIST Cybersecurity Framework. The organization is also ISO 27001 certified. The successful completion of Benchling's Type 2 SOC 2 inspection assures that its biotech clients can conduct crucial R&D work in the Benchling R&D Cloud while following the highest security requirements. About Benchling Benchling is a San Francisco-based firm that focuses on private and public life science cooperation by developing cloud-based software tools for digital DNA sequence editing, planning and performing experiments, evaluating data, and sharing research. More than 200,000 scientists from over 1,000 firms and 7,500 university and research institutions worldwide have used the Benchling R&D Cloud to create breakthrough discoveries and deliver the next generation of medicines, foods, and materials to market more quickly. In addition, the R&D cloud assists these companies in modernizing their scientific processes and accelerating their cooperation to transform the complexity of biology into world-changing outcomes.

Read More


Resilience Partners with a Major Pharmaceutical Company for Strategic Biomanufacturing

Resilience | February 20, 2023

National Resilience, Inc. (Resilience), a manufacturing company with a technology-focused mission to improve access to complex medications, recently announced a 10-year biomanufacturing partnership with a top pharmaceutical company for its portfolio of services in process and analytical development, drug substance manufacturing, and drug product manufacturing. The extensive agreement covers prospective biologic, vaccine, nucleic acid, cell, and gene therapy manufacturing. Resilience’s recently acquired facility in Cincinnati, Ohio, is its worldwide center of excellence to produce commercial medicinal products, and will deliver the first product as stipulated under the agreement. The development of complicated pharmaceuticals, such as cell and gene therapies, has not kept up with the rate of scientific advancements that are supporting them. Resilience brings together exceptional minds in science and engineering to bridge this gap with access to state-of-the-art technology. Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience, said, “The partnership announced today is a major milestone for Resilience.” He further added, “We are grateful to have this opportunity to work with our partner to deliver important, life-saving medicines to patients. We understand the trust placed with us to manufacture the medicine with the highest quality, regulatory compliance, and reliability. We are committed to maintaining a responsible manufacturing operation that exceeds the expectations of our partners and enables us to make a meaningful impact on global healthcare.” (Source – Business Wire) With the addition of this alliance to its expanding commercial portfolio, the company anticipates generating record revenues in 2023. About Resilience Resilience is a technology-focused biomanufacturing startup. The company intends to increase access to sophisticated medications. The firm is establishing a long-term network of cutting-edge, all-inclusive manufacturing solutions to guarantee that the therapies of today and the future may be produced efficiently, securely, and at scale. Resilience aims to continuously develop the science of biopharmaceutical manufacture and development, so their partners concentrate on the discoveries that enhance patients' lives and safeguard biopharmaceutical supply chains from future disruptions.

Read More